A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)

• Status: Completed
• Trial end date: 2020-06-25

Summary

A phase IV, multicentre, randomised, open-label, pilot clinical trial to evaluate the Reversibility of abacavir/lamivudine/dolutegravir ( ABC/3TC/DTG) CNS-Related Neurotoxicity After Switching to tenofovir alafenamide/emtricitabine/darunavir/cobicistat (TAF/FTC/DRV/c)

• Phase: Phase 4

Details

• Lead Sponsor: Fundacion SEIMC-GESIDA
• Collaborator: Janssen-Cilag, S.A.
• Treatments: Abacavir; Cobicistat; Darunavir; Dolutegravir; Emtricitabine; Lamivudine; Tenofovir